FIELD: medicine.
SUBSTANCE: there are presented versions of the peptide (A) or (B) with the amino acid sequence of SEQ ID NO: 1 or 2 respectively presented in this description. The peptide has activity to induce a cytotoxic T-cell when an antigen-presenting cell carrying HLA-A2 (A*0201) presents it. There are described the versions of the peptide antibodies prepared by immunisation by the proper peptide. There are presented: an agent, methods for inducing: a cytotoxic (killer) T-cell, an antigen-presenting cell, CDH3 expressing cancer immunity; as well as a method of treating CDH3 expressing cancer on the basis of the peptide. What is presented is an isolated cytotoxic T-cell induced by said method on the basis of the peptide. There are described: the antigen-presenting cell and exosome presenting the complex containing the peptide and HLA-A2 (A*0201).
EFFECT: higher effectiveness of the use of the invention in treating CDH3 expressing cancer.
15 cl, 5 dwg, 2 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CDC45L PEPTIDES AND VACCINES CONTAINING SAME | 2010 |
|
RU2562160C2 |
| FOXM1 PEPTIDES AND VACCINES CONTAINING THEM | 2010 |
|
RU2560431C2 |
| FOXM1 PEPTIDE AND MEDICINAL AGENT CONTAINING SAID PEPTIDE | 2008 |
|
RU2487886C2 |
| MODIFIED MELK PEPTIDES AND VACCINES CONTAINING LATTER | 2011 |
|
RU2580035C2 |
| EPITOPIC PEPTIDES RAB6KIFL/KIF20A AND VACCINES CONTAINING THEM | 2009 |
|
RU2532105C2 |
| URLC10-DERIVED PEPTIDE AND VACCINE CONTAINING SAME | 2015 |
|
RU2700881C2 |
| PEPTIDE CANCER VACCINES EXPRESSING TUMOUR-SPECIFIC ANTIGENS | 2008 |
|
RU2464275C2 |
| CDCA1 PEPTIDE AND PHARMACEUTICAL DRUG CONTAINING IT | 2008 |
|
RU2486195C2 |
| CDCA1 EPITOPE PEPTIDES AND VACCINES CONTAINING SAME | 2009 |
|
RU2502740C2 |
| HLA A*3303-RESTRICTED PEPTIDE WT1 AND PHARMACEUTICAL COMPOSITION CONTAINING SAID PEPTIDE | 2007 |
|
RU2435782C2 |
